Syphilis in pregnancy

Clinical Guideline Presentation v5.0





References:

Queensland Clinical Guideline: Syphilis in pregnancy is the primary reference for this package.

Recommended citation:

Queensland Clinical Guidelines. Syphilis in pregnancy clinical guideline education presentation E18.44-1-V5-R23. Queensland Health. 2023.

Disclaimer:

This presentation is an implementation tool and should be used in conjunction with the published guideline. This information does not supersede or replace the guideline. Consult the guideline for further information and references.

Feedback and contact details:

M: GPO Box 48 Brisbane QLD 4001 | E: guidelines@health.qld.gov.au | URL: www.health.qld.gov.au/qcg

Funding:

Queensland Clinical Guidelines is supported by the Queensland Health, Healthcare Improvement Unit.

Copyright:

© State of Queensland (Queensland Health) 2023



This work is licensed under a Creative Commons Attribution Non-Commercial No Derivatives 4.0 Australia licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the Queensland Clinical Guidelines Program, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en

For further information contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email quidelines@health.qld.gov.au. For permissions beyond the scope of this licence contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip officer@health.qld.gov.au. Images are property of State of Queensland (Queensland Health) unless otherwise cited.

Learning objectives

- Recall basic pathophysiology of syphilis in pregnancy and congenital syphilis in the newborn
- Identify recommended screening according to risk assessment
- Identify indications for maternal and neonatal treatment

OBJECTIVES

Aetiology of syphilis

Syphilis is a bacterial infection caused by the spirochaete bacterium *Treponema* pallidum (*T. pallidum*)



Syphilis, and congenital syphilis, are notifiable diseases in Queensland

Transmission

Transmission of syphilis can occur in multiple ways including:

- Direct contact with infectious lesions (chancre)—most commonly through sexual contact
- Vertical transmission—transplacental during pregnancy
- Less commonly through infected blood
- Incubation period is approximately 21 days from contact to the development of a chancre





Assessment



Identify increased & higher risk groups

Maternal, obstetric and sexual history

Offer screening for sexually transmitted diseases (STIs)

Conduct clinical examination

Dry swab suspicious genital lesions for polymerase chain reaction (PCR)

Request Syphilis serology on pathology form



Stages of syphilis

Primary (Infectious)

- Lesions may be solitary or multiple
- Lesions may be painful or painless
- Spontaneously heal within 3–10 weeks without treatment

Secondary (Infectious)

- Follows untreated primary syphilis 4–8 weeks after first lesion
- Rash to palms and soles of feet
- Resolves without treatment in 3–12 weeks

Latent


- Follows untreated secondary stage
- Asymptomatic
- Reactive serology with no clinical manifestations

Tertiary

- Can affect any organ system
- Occurs in one-third of untreated patients



Treponema pallidum















Images from the Centre for Disease Control and Prevention (CDC) 2018


Additional screening



High risk of syphilis

- Sexual contact with an infectious syphilis case
- Woman or her partner(s) identify as Aboriginal and/or Torres Strait Islander AND the woman or her partner(s) reside in declared outbreak area
- Substance use during pregnancy—particularly ('ice')
- Woman's partner is a man who has sex with men
- Late, limited or no antenatal care
- Engages in high risk sexual activity

Recommended testing



Maternal treatment

Infectious syphilis requiring treatment (primary or secondary)

Benzathine penicillin 1.8 g (2.4 million units) IM as a single dose

NB: if syphilis requiring treatment is suspected and there is concern the woman will not re-present for care—presumptively give the recommended treatment

Late latent or syphilis of unknown duration requiring treatment

Benzathine penicillin 1.8 g (2.4 million units) IM weekly for three weeks

Postpartum maternal testing

Repeat maternal syphilis serology at birth if:

- Syphilis requiring treatment during pregnancy
- Woman is High risk
- No repeat serology after 26 weeks AND any
 - Preterm birth with most recent serology
 four weeks before birth
 - Woman or partner(s) identify as Aboriginal and/or Torres Strait Islander
 - Adolescent pregnancy
 - STI in the current pregnancy or preceding 12 months
 - Woman and/or partner(s) have ongoing sexual links in high prevalence countries (e.g. migrants or refugees)
 - If indicated following risk assessment

If syphilis requiring treatment, maternal serological follow-up at:


- Three months
- Six months and
- 12 months

Discuss with QSSS and expert practitioner if:

- Maternal titre not decreased four-fold within 12 months OR
- There is a four-fold increase

Aetiology of congenital syphilis (CS)

Cause: the spirochaete bacterium *Treponema* pallidum (*T. pallidum*) crossing the placenta, from the mother who has reactive serology





Babies at risk of CS

Suspect CS in babies born to women who:

- Had syphilis requiring treatment in pregnancy (irrespective of adequacy of treatment)
- Limited or no antenatal care
- Diagnosed with syphilis (any stage) within three months postpartum



Diagnosis of CS

NB: Do not delay treatment while waiting for prenatal diagnostic tests

Prenatal diagnosis

- Ultrasound examination
- Maternal diagnosis

Diagnosis at birth

- Conduct full clinical examination
- Collect syphilis serology (do not collect blood from umbilical cord)
- Placental histopathology (collect entire fresh placenta for testing)

Additional diagnostic tests for consideration

- Cerebrospinal fluid (CSF) testing
- Haematology
- Radiography

Signs and symptoms of CS

60–90% of babies are asymptomatic at birth
Signs and symptoms are usually subtle and non-specific
Usually appear by three months of age, most often by 5 weeks

- Hepatomegaly
- Rhinitis
- Rash
- Generalised lymphadenopathy
- Nonimmune fetal hydrops
- Fever/sepsis
- Failure to move extremities secondary to pain
- Ophthalmologic manifestations
- Gastrointestinal manifestations







Treatment

NB: If a dose is missed restart the entire treatment regimen

Newborn 0–7 days of age

Recommended:

Benzyl penicillin 30 mg/kg IV 12 hourly for 10 days

Alternative: Procaine penicillin 50mg/kg IM daily for 10 days

Newborn 8–30 days of age

Recommended:

Benzyl penicillin 30 mg/kg IV 8 hourly for 10 days

Alternative: Procaine penicillin 50mg/kg IM daily for 10 days

Newborn more than 30 days of age

Recommended:

Benzyl penicillin 30 mg/kg IV 4–6 hourly for 10 days

Alternative: Procaine penicillin 50mg/kg IM daily for 10 days

Newborn follow up



- Follow-up serology:
 - At three, six and 12 months of age
 - If non-reactive at 12 months, no further testing required
- If follow-up testing is potentially difficult:
 - Aim to repeat testing at least twice in the first six months of life (with at least four weeks between tests)
 - Consider feasibility of testing at routine follow up appointments (e.g. immunisation, infant health checks)
- If initial newborn serology is non-reactive in the reactive mother, follow-up at three and six months
- If serology remains non-reactive at six months, no further testing is required

Case study: Syphilis

- Mary is a 30 year old multigravida. She lives in a syphilis outbreak declared area and identifies as an Aboriginal and Torres Strait Islander woman.
- She returns to the hospital reporting that her baby Alexander, now 12 days of age, was suffering from a white discharge from his nose (resolved at day 5).
- Alexander has developed a rash on his back and feet and cries when he tries to move his legs
- When you review Mary's chart you notice that she had non-reactive syphilis serology at her booking-in visit at 26 weeks. She then had a reactive serology test at birth but no treatment or follow up was documented

Clinical indicators

What indicators for syphilis and congenital syphilis do you identify from Mary's presentation?

- Mary identifies as an Aboriginal and Torres Strait Islander and resides in a syphilis declared outbreak area
- Late antenatal booking in with no follow-up serology based on risk category
- Reactive syphilis serology antenatally
- Baby Alexander has signs of congenital syphilis (rhinitis, rash and failure to move extremity secondary to pain (pseudoparalysis of Parrot)
- Mary is multigravida—? risk of previous babies born with syphilis

Communication

What questions might you consider asking Mary?

- Some of our activities in life can make us at a higher risk for syphilis. Have you ever taken any illegal drugs before? How many sexual partners do you have? Have you ever been treated for an STI?
- Have you, or your partners, ever tested positive to syphilis before?
- Have you, or your partners, ever been treated for syphilis before?
- How many other children do you have? How old are they? Did any of your other children have signs or symptoms of congenital syphilis?

Testing and treatment

What tests do you recommend to Mary and baby Alexander?

Mary:

Syphilis serology on pathology request form

Baby Alexander:

- Syphilis serology pathology request
- Consider CSF test (consult with expert health practitioner)

What treatment would you recommend?

Mary:

 Benzathine penicillin 1.8 gm (2.4 million units) IM as a single dose

Baby Alexander:

 Benzyl penicillin 30 mg/kg IV 8 hourly for 10 days

NB: all treatment in consultation with an expert practitioner



Communication

Who will you communicate with?

- Expert health practitioner/s
- Queensland Syphilis Surveillance Unit
- Discuss contact management with Mary
- Importance of treatment
- Communicate with other health practitioners through documentation in clinical notes
- Aboriginal and/or Torres Strait Islander liaison, as required